ATCC (American Type Culture Collection)
ATCC is a nonprofit biological resource center, with a nearly century-long legacy supporting public health, biodefense, and global health security. ATCC provides critical infrastructure for infectious disease research and CBR threat response. Our biorepository operations support federal agencies, academia, and industry through secure specimen handling, reagent authentication, and global distribution. ATCC manages over 22 million vials under federal contracts, including repositories for NIAID, CDC, BARDA, NCI, FDA, and USDA. These programs enable rapid deployment of validated biological materials for vaccine development, diagnostic assay verification, and therapeutic screening against high-consequence pathogens such as SARS-CoV-2. Certified under ISO 9001, 13485, 17025, and 17034, ATCC ensures quality, traceability, and regulatory compliance across its operations. Our high-containment laboratories (BSL-2 and BSL-3, with access to BSL-4 through partners) and Select Agent license position us to support MTEC-aligned efforts in emerging infectious diseases and medical countermeasure development for CBRN threats.
ATCC (American Type Culture Collection)
10801 University Blvd, Manassas, VA 20110, USA
Patents
What We Do
Standards & Research Tools
For decades we have supported government agencies with curated, high-quality biomaterials and resources, laboratory services, and repository operations. We offer services including on- and off-site repository management, the creation of new repositories, facilitating repository consolidations, and transferring management of existing repositories. We also support your high-quality research for the government by providing complete laboratory services, including aliquoting and biospecimen processing. We provide time-tested protocols for sample acquisition, receipt, production, expansion, maintenance, storage, distribution, and disposition of research materials, including pathogens and their derivatives, reagents, human biospecimens, and investigational products.
Global Health & Biosecurity
ATCC plays a critical role in global health and biosecurity by supporting federal partners with high-quality biological materials, specialized laboratory services, and scientific expertise tailored to CBRN preparedness and infectious disease response. Through its extensive resources, ATCC facilitates the development of medical countermeasures, provides essential reagents and challenge stocks for high-consequence pathogens such as SARS-CoV-2 and Zika, and ensures secure biorepository and logistics management for clinical materials. The organization also contributes subject matter expertise to federal working groups and manages contracts such as BEI Resources and the CDC's International Reagent Resource, reinforcing national and international capabilities to address Category A, B, and C biological threats.
Biomanufacturing
x
Services
Show More (2)Key People
Senior Vice President, ATCC Federal Solutions
Director, Government Programs, ATCC Federal Solutions (AFS)
Director, Contracts, ATCC Federal Solutions (AFS)
News & Updates
Ruth Cheng, appointed new president and CEO of ATCC, succeeds Raymond Cypess, who will remain on the Board of Directors as chairman.
NCI awarded ATCC a 5-year contract with a ceiling value of $4.06 million to provide lab services that support HIV and HTLV-1 research and vaccine development.
ATCC awarded a one-year, subaward in the amount of $165,962 from NIAID to collaborate on babesiosis and tickborne disease research.
ATCC received a C06 Research Facilities Construction Grant from ORIP, part of the NIH, to support the building of ATCC’s new biomanufacturing suite at its headquarters in Manassas, VA.
ATCC was awarded a contract to develop well-characterized challenge materials, enhancing their capabilities in infectious disease research.
A discussion on the importance of a unified approach to infectious disease management.